Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

Reduction in BP Drives Treatment Preference for Hypertensive Patients

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

November 18, 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

News Daily News

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

November 01, 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Hints of Benefit With Catheter-Directed Thrombolysis in Intermediate/High-Risk PE

News Daily News

Hints of Benefit With Catheter-Directed Thrombolysis in Intermediate/High-Risk PE

October 19, 2022

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal Care Resumes

News Daily News

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Michael O'Riordan

October 18, 2022

Two RCTs Add Needed Evidence for Thrombectomy in Basilar Occlusion

News Daily News

Two RCTs Add Needed Evidence for Thrombectomy in Basilar Occlusion

October 13, 2022

What Do the Clinical Trials Tell Us to Do in Intermediate-Risk PE?

Presentation TCT 2022

What Do the Clinical Trials Tell Us to Do in Intermediate-Risk PE?

Presenter: Eric Secemsky

September 19, 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

News Conference News TCT 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

September 18, 2022

TCT 211: Home Blood Pressure Response to Ultrasound Renal Denervation - a Patient-level Pooled Analysis of the RADIANCE-HTN SOLO and TRIO Randomised, Sham-controlled Trials

Presentation

TCT 211: Home Blood Pressure Response to Ultrasound Renal Denervation - a Patient-level Pooled Analysis of the RADIANCE-HTN SOLO and TRIO Randomised, Sham-controlled Trials

Presenter: Andrew Sharp

September 17, 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 07, 2022

TCTMD’s Top 10 Most Popular Stories for August 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2022

September 01, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

AHA, CRF Announce Partnership for 2022 Fall Meeting Sessions

News Daily News

AHA, CRF Announce Partnership for 2022 Fall Meeting Sessions

August 15, 2022

CASSISS: No Benefit of Stenting for Intracranial Stenosis

News Daily News

CASSISS: No Benefit of Stenting for Intracranial Stenosis

August 12, 2022

RESCUE BT: IV Tirofiban No Help During Stroke Thrombectomy

News Daily News

RESCUE BT: IV Tirofiban No Help During Stroke Thrombectomy

August 09, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.